Restoring an adequate dietary fiber intake by inulin supplementation: a pilot study showing an impact on gut microbiota and sociability in alcohol use disorder patients.

Camille Amadieu, Valentin Coste, Audrey M Neyrinck, Victoria Thijssen, Quentin Leyrolle, Laure B Bindels, Hubert Piessevaux, Peter Stärkel, Philippe de Timary, Nathalie M Delzenne, Sophie Leclercq

Journal: Gut microbes 2022;14(1):2007042

PMID: 34923905

Abstract

Alcohol use disorder (AUD) is a chronic relapsing disease associated with malnutrition, metabolic disturbances, and gut microbiota alterations that are correlated with the severity of psychological symptoms. This study aims at supplementing AUD patients with prebiotic fiber during alcohol withdrawal, in order to modulate the gut microbiota composition and to evaluate its effect on gastrointestinal tolerance, metabolism, and patient's behavior. A randomized, double-blind, placebo-controlled study included 50 AUD patients assigned to inulin maltodextrin daily supplementation for 17 days. Biological measurements (fecal microbial 16S rDNA sequencing, serum biology), dietary intake, validated psychological questionnaires, and gastrointestinal tolerance assessment were performed before and after the intervention. Inulin significantly decreased the richness and evenness and induced changes of 8 genera (q < 0.1) including and . Prebiotic had minor effects on gastrointestinal symptoms and nutritional intakes compared to placebo. All patients showed an improvement in depression, anxiety, and craving scores during alcohol withdrawal regardless of the intervention group. Interestingly, only patients treated with inulin significantly improved the sociability score and had an increased serum level of brain-derived neurotrophic factor. This pilot study shows that inulin is well tolerated and modulates the gut microbiota and the social behavior in AUD patients, without further improving other psychological and biological parameters as compared to placebo. Gut2Brain study, clinicaltrial.gov: NCT03803709, https://clinicaltrials.gov/ct2/show/NCT03803709.

Address: Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université Catholique De Louvain, UCLouvain, Brussels, Belgium.; Institute of Neuroscience, Université Catholique De Louvain, UCLouvain, Brussels, Belgium.; Department of Hepato-Gastroenterology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.; Institute of Experimental and Clinical Research, Laboratory of Hepato-Gastroenterology, Université Catholique De Louvain, UCLouvain, Belgium.; Department of Adult Psychiatry, Cliniques Universitaires Saint Luc, Brussels, Belgium.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.